trimethaphan
Trade name: arfonad
Approved
Apr 26, 1954
Trimethaphan (or Trimethaphan camsylate), a ganglionic blocking agent and an antihypertensive drug, was marketed under the brand name Arfonad. Arfonad is indicated to induce systemic arterial hypotension in patients undergoing major surgery and to treat severe systemic hypertension, and in the emergency treatment of pulmonary edema in patients with pulmonary hypertension associated with systemic hypertension. Trimethaphan prevents stimulation of postsynaptic receptors by competing with acetylcholine for these receptor sites. Additional effects may include direct peripheral vasodilation and release of histamine. This drug was discontinued because of the competition from newer drugs that are more selective in their actions and effects. — NCATS
Clinical trial activity
9 trials · 2 clinical orgs · 1 marketing orgs
Earliest trial started Aug 1, 2002 (NCT00178919)
Timeline
Indications
Approved for
Studied for
- Endothelial Cells · Phase 1
- Essential Hypertension · Phase 1
- Fatigue Syndrome, Chronic · Phase 1
- Hypertension · Phase 1
- Hypotension, Orthostatic · Phase 1
- Insulin Resistance · Phase 1
- Multiple System Atrophy · Phase 1
- Obesity · Phase 1
- Orthostatic Intolerance · Phase 1
- Postural Orthostatic Tachycardia Syndrome · Phase 1
- Pure Autonomic Failure · Phase 1
- Shy-Drager Syndrome · Phase 1
Mechanism of action
Neuronal acetylcholine receptor; alpha3/beta4 antagonist
Approval history
- approvedPriority reviewApr 26, 1954
Chemistry & pharmacology
SMILES
O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1- Mol. weight
- 365.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1201329 ↗
- WikipediaTrimetaphan camsilate ↗
- NCATS6G8X656T45 ↗
- ChEMBLCHEMBL1245 ↗
Also known as
- arfonad
- arfonad
- arfonad
- arfonad
- arfonad
- decahydro-2-oxo-1,3-bis(phenylmethyl)thieno(1',2':1,2) thieno(3,4-d)imidazol-5-ium, salt with (1s)-7,7-dimethyl-2-oxobicyclo(2.2.1)heptane-1-methanesulfon ic acid (1:1)
- thimethaphan
- thimethaphan
- trimetaphan
- trimetaphan
- trimetaphan
- trimetaphan
- trimetaphan
- trimetaphan camsilate
- trimetaphan camsilate
- trimetaphan camsylate
- trimetaphan camsylate
- trimetaphan camsylate
- trimetaphanum
- trimetaphanum
- trimethaphan
- trimethaphan
- trimethaphan
- trimethaphan
- trimethaphan
- trimethaphan
- trimethaphan
- trimethaphan
- trimethaphan
- trimethaphan
- trimethaphan camphorsulfonate
- trimethaphan camphorsulfonate
- trimethaphan camphorsulfonate
- trimethaphan camphor sulfonate
- trimethaphan camsylate
- trimethaphan camsylate
- trimethaphan camsylate
- trimethaphan camsylate
- trimethaphan camsylate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03028571 | Phase 1 | Feb 17, 2017 | Vanderbilt University |
| NCT02726711 | Phase 1 | Apr 1, 2016 | Vanderbilt University |
| NCT02425566 | Phase 1 | Apr 1, 2015 | Vanderbilt University |
| NCT02245230 | Phase 1 | Sep 1, 2014 | Vanderbilt University |
| NCT01137253 | Phase 1 | Jun 1, 2010 | Vanderbilt University |
| NCT01122407 | Phase 1 | Jan 1, 2010 | National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University |
| NCT00580619 | Phase 1 | Apr 1, 2007 | Vanderbilt University |
| NCT00179023 | Phase 1 | Apr 1, 2003 | Vanderbilt University |
| NCT00178919 | N/A | Aug 1, 2002 | Vanderbilt University |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vanderbilt University | Academic/Hospital | 9 | 9 | 2 | 2002 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2010 |